The large list ofactivators of PPAR-γ includes prostaglandin-derived 15-deoxi-delta 12,14PGJ2 (15d-PGJ2), the thiazolidinediones(TZD) troglitazone (RezulinR), pioglitazone (ActosR),and rosiglitazone (AvandiaR), among others (seeTable 1) [2, 10, 20].The currently marketed TZDs are potent and selective PPAR-γ activators; they areantidiabetic agents that increase the insulin sensitivity of target tissues inanimal models of non-insulin-dependent diabetes mellitus and in diabeticpatients. Here, PPARG is linked to type 1 diabetes mellitus.